Recent News

• 04.21.2025 - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
• 04.21.2025 - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
• 04.09.2025 - Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
• 04.09.2025 - Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
• 03.27.2025 - Tempest Reports Year End 2024 Financial Results and Provides Business Update
• 03.27.2025 - Tempest Reports Year End 2024 Financial Results and Provides Business Update
• 03.25.2025 - Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
• 03.25.2025 - Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
• 03.13.2025 - FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
• 03.13.2025 - FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Recent Filings

• 04.18.2025 - 8-K Current report
• 04.09.2025 - EX-99.1 EX-99.1
• 04.09.2025 - 8-K Current report
• 04.07.2025 - 8-K Current report
• 03.27.2025 - 8-K Current report
• 03.27.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.11.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership